- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00983697
FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer (ACRIN6685)
A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET/CT scan, may help doctors find head and neck cancer and find out how far the disease has spread. It may also help doctors plan the best treatment.
PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing the tumor and planning neck surgery in patients with newly diagnosed head and neck cancer.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
OBJECTIVES:
Primary
- Determine the negative predictive value of PET/CT imaging based upon pathologic sampling of the neck lymph nodes in patients with head and neck cancer planning to undergo N0 neck surgery.
- Determine the potential of PET/CT imaging to change treatment.
Secondary
- Estimate the sensitivity and diagnostic yield of PET/CT imaging for detecting occult metastasis in the clinical N0 neck (both by neck and lymph node regions) or other local sites.
- Determine the effect of other factors (e.g., tumor size, location, secondary primary tumors, or intensity of FDG uptake) that can lead to identification of subsets of patients that could potentially forego neck dissection or that can provide preliminary data for subsequent studies.
- Compare the cost-effectiveness of using PET/CT imaging for staging head and neck cancer vs current good clinical practices.
- Evaluate the incidence of occult distant body metastasis discovered by whole-body PET/CT imaging.
- Correlate PET/CT imaging findings with CT/MRI findings and biomarker results.
- Evaluate the quality of life of these patients, particularly of those patients whose management could have been altered by imaging results.
- Evaluate PET/CT imaging and biomarker data for complementary contributions to metastatic disease prediction.
- Compare baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of recurrence, disease-free survival, and overall survival.
- Determine the proportion of neck dissections that are extended (i.e., additional levels that clinicians intend to dissect beyond the initial surgery plan) based on local-reader PET/CT imaging findings shared with the surgeon before dissection.
- Estimate the optimum cutoff value of standardized uptake values for diagnostic accuracy of PET/CT imaging.
- Evaluate the impact of PET/CT imaging on the N0 neck across different tumor subsites (defined by anatomic location).
OUTLINE: This is a multicenter study.
Patients undergo fludeoxyglucose F 18-PET/CT imaging. Approximately 14 days later, patients undergo unilateral or bilateral neck dissection.
Patients complete quality-of-life questionnaires at baseline and at 1, 12, and 24 months after surgery.
Patients undergo blood and tissue sample collection periodically for biomarker analysis.
Patients are followed up periodically for up to 2 years after surgery.
Tanulmány típusa
Beiratkozás (Várható)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Arkansas
-
Little Rock, Arkansas, Egyesült Államok, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Los Angeles, California, Egyesült Államok, 90089-9181
- USC/Norris Comprehensive Cancer Center and Hospital
-
-
Florida
-
Safety Harbor, Florida, Egyesült Államok, 34695
- Morton Plant Mease Cancer Care at Mease Countryside Hospital
-
Tampa, Florida, Egyesült Államok, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
-
-
Kentucky
-
Louisville, Kentucky, Egyesült Államok, 40245
- Jewish Hospital Heart and Lung Institute
-
-
Minnesota
-
Rochester, Minnesota, Egyesült Államok, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Egyesült Államok, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
North Carolina
-
Winston-Salem, North Carolina, Egyesült Államok, 27157
- Wake Forest University Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Egyesült Államok, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok, 19107
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
-
-
-
-
Beijing, Kína, 100730
- Peking Union Medical College Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
DISEASE CHARACTERISTICS:
Histologically confirmed newly diagnosed squamous cell carcinoma (SCC) of the head and neck , including any of the following sites:
- Oral cavity
- Oropharynx, including base of tongue and tonsils
- Larynx
- Supraglottis
Stage T2-T4, N0-N3 disease
Unilateral or bilateral neck dissection planned
- No N2c disease (if bilateral disease is present)
Has ≥ 1 clinically N0 neck side as defined by clinical exam (physical exam with CT scan and/or MRI)
- A N0 neck must be planned to be dissected for the patient to be eligible
- . The N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is planned
CT scan and/or MRI taken within the past 4 weeks to confirm SCC of the head and neck
- Simultaneous diagnostic CT with PET scan allowed; however, PET cannot be used as part of the criteria to define the N0 neck disease
- For CT scan and/or MR images from other institutions, ACRIN recommends a re-read by a local neuro-radiologist to ensure compliance
- No sinonasal cancer, salivary gland cancer, thyroid cancer, nasopharyngeal cancer, or advanced skin cancer
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Negative pregnancy test
- Weight ≤ 350 lbs
- No poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications (optimally, patients will have glucose < 150 mg/dL)
- No underlying medical condition that would preclude surgery (neck dissection)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Diagnosztikai
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: FDG PET/CT
Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Negative predictive value of PET/CT imaging for staging the N0 neck based upon pathologic sampling of the neck lymph nodes
Időkeret: Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
True negative cases will be determined by histopathology reports.
The test will be defined as positive when SUVmax value of ≥ 2.0; and negative otherwise.
|
Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Sensitivity and diagnostic yield of PET/CT imaging for detecting occult metastasis in the clinically N0 neck (both by neck and lymph node regions) or other local sites
Időkeret: Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
True positive cases will be determined by histopathology reports.
The test will be defined as positive when SUVmax value of ≥ 2.0; and negative otherwise.
The diagnostic yield is defined as the ratio of cancers to total screened
|
Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
Determine which factors (e.g., tumor size, secondary primary tumors, location, or intensity of FDG uptake) may identify patients who can forego neck dissection
Időkeret: Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
True positive cases will be determined by histopathology reports.
The test will be defined as positive when SUVmax value of ≥ 2.0; and negative otherwise.
The diagnostic yield is defined as the ratio of cancers to total screened
|
Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
Cost-effectiveness and cost-benefit of using PET/CT imaging for staging of head and neck cancer vs current good clinical practices
Időkeret: 2 years post-surgery
|
The outcome measure will use the total cost of care for each participant to compute the incremental cost-effectiveness ratio (ICER)
|
2 years post-surgery
|
Incidence of occult distant body metastasis discovered by whole body PET/CT imaging
Időkeret: Within Two Weeks Before Surgery
|
this outcome will count the distant body metastasis not previously seen and report the results as a percentage.
|
Within Two Weeks Before Surgery
|
Correlation of PET/CT imaging findings with CT/MRI findings and biomarker results
Időkeret: Within Two Weeks Before Surgery
|
the outcome measure will consist of paired proportions of dichotomized PET/CT and CT/MRI test results; and biomarker test results
|
Within Two Weeks Before Surgery
|
Quality of life (QOL), particularly in patients whose management could have been altered by imaging results
Időkeret: 2 years post-surgery
|
QOL will be assessed using SF-36, Non-Utility HUI, and UW-QoL scores
|
2 years post-surgery
|
Evaluation of the PET/CT imaging and biomarker data for complementary contributions to metastatic disease prediction
Időkeret: Within Two Weeks Before Surgery
|
the metastatic disease status is the response variable and PET/CT test results and biomarker data are predictors.
|
Within Two Weeks Before Surgery
|
Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of recurrence
Időkeret: 2 years post-surgery
|
model the associations of PET/CT test results and biomarker data (predictors) to recurrence
|
2 years post-surgery
|
Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of disease-free survival
Időkeret: 2 years post-surgery
|
model the associations of PET/CT test results and biomarker data (predictors) to disease-free survival
|
2 years post-surgery
|
Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of overall survival
Időkeret: 2 years post-surgery
|
model the associations of PET/CT test results and biomarker data (predictors) to overall survival (censored responses)
|
2 years post-surgery
|
Proportion of neck dissections that are extended based on local-reader PET/CT imaging findings shared with the surgeon before dissection
Időkeret: Within Two Weeks Before Surgery
|
Outcome is defined as the number patients who surgeons intend to dissect levels beyond the initial surgery plan
|
Within Two Weeks Before Surgery
|
Optimum cutoff value of standardized uptake values for diagnostic accuracy of PET/CT imaging
Időkeret: Within Two Weeks Before Surgery
|
ROC analysis will be used to maximize the youden index and estimate the optimum cutoff value of SUV for diagnostic accuracy of PET/CT on N0 neck
|
Within Two Weeks Before Surgery
|
Impact of PET/CT imaging on the N0 neck across different tumor subsites (defined by anatomic location)
Időkeret: Within Two Weeks Before Surgery
|
Diagnostic Accuracy measures will be calculated using ROC analysis, subset by anatomic location
|
Within Two Weeks Before Surgery
|
Együttműködők és nyomozók
Együttműködők
Nyomozók
- Tanulmányi szék: Val J. Lowe, MD, Mayo Clinic
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Várható)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
- stádiumú ajak- és szájüreg laphámsejtes karcinóma III
- stádiumú szájüreg verrucous carcinoma III
- stádiumú ajak- és szájüreg laphámsejtes karcinóma IV
- stádiumú szájüreg verrucous carcinoma IV
- stádiumú oropharynx laphámsejtes karcinóma III
- stádiumú oropharynx laphámsejtes karcinóma IV
- stádiumú gége laphámsejtes karcinóma III
- stádiumú gége laphámsejtes karcinóma IV
- stádiumú ajak- és szájüreg laphámsejtes karcinóma
- stádiumú gége laphámsejtes karcinóma
- stádiumú oropharynx laphámsejtes karcinóma
- nyelvrák
- stádiumú szájüreg verrucous carcinoma II
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- CDR0000654703
- U01CA080098 (Az Egyesült Államok NIH támogatása/szerződése)
- U01CA079778 (Az Egyesült Államok NIH támogatása/szerződése)
- ACRIN-6685 (Egyéb azonosító: CIP ID)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
See ACRIN data sharing policy:
https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx
IPD megosztási időkeret
IPD-megosztási hozzáférési feltételek
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a terápiás hagyományos műtét
-
Diakonessenhuis, UtrechtToborzásÉletminőség | Alvási apnoe, obstruktívHollandia
-
Boston Medical CenterMég nincs toborzásAnyaghasználati zavarok | Mentális egészséggel kapcsolatos problémaEgyesült Államok
-
Royal Surrey County Hospital NHS Foundation TrustIsmeretlenPetefészekrák | Petevezető rák | Peritoneális rák | Petefészek neoplazma | Petefészek neoplazma epiteliálisEgyesült Királyság
-
Cognoa, Inc.MegszűntAutizmus spektrum zavarEgyesült Államok
-
University Hospital Inselspital, BerneBefejezveVéletlenszerű, kontrollált próba | Kamrai peritoneális sönt | Sönt szövődmények | Shunt FailureSvájc
-
ARCAGY/ GINECO GROUPToborzásA petefészekrák IIIC stádiuma | A petefészekrák IV | Petefészekrák IIIb stádiumFranciaország
-
National Development and Research Institutes, Inc.National Institute on Drug Abuse (NIDA)BefejezveAnyaggal kapcsolatos rendellenességek | Mentális zavarokEgyesült Államok
-
Bar-Ilan University, IsraelUniversity of Haifa; Israel Science FoundationBefejezve
-
Assiut UniversityMég nincs toborzás
-
Medacta International SAToborzásAz elülső keresztszalag (ACL) rekonstrukciójaAusztria, Németország